Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.